Sign inJoin free

Watch / Small Cap

LTR Pharma's scale-up post IPO

30 Apr 20245:09

LTR Pharma's scale-up post IPO

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Key highlights:

  • LTR Pharma's first clinical trial for Spontan, a nasal spray treatment for erectile dysfunction

  • The speed and efficiency of Spontan compared to other treatments

  • LTR Pharma's financial position and future plans, including a potential launch in Australia

Lee Rodne of LTR Pharma provides an update on his company's latest quarterly activities. The company has initiated its first clinical trial for a nasal spray treatment for erectile dysfunction, known as Spontan. With recruitment and dosing of all patients complete, LTR Pharma is now in the data analysis phase.

The final results will be announced in the following quarter.,Lee emphasises that Spontan is a pioneering innovation in erectile dysfunction treatment, bypassing the digestive system to potentially work within 5 to10 minutes instead of up to an hour for conventional treatments like Viagra. Notably, the quick recruitment for the study suggests a strong consumer demand for Spontan.

Looking forward, Lee highlights the company's plans to ramp up manufacturing for a launch in Australia in the second half of the year through special and early access programmes. Moreover, he emphasises the company's strong financial position, with a successful IPO in December providing the necessary funds for key milestones and regulatory submissions. The company will be seeking early revenues in the latter half of the year. Lee also expresses his anticipation for Spontan's approval on the PBS, slated for 12 to 18 months from now.

Below is an unedited transcript of the interview:

Let's get company specific now and look at one firm's latest quarterly activities report. LTR Pharma is out with its numbers. And Lee Rodne, LTR Pharma Executive Chairman, joins me now. Um, quite a productive quarter. Talk us through it, Lee. And also your, uh, proposition on the spon tan product. What is that?

0:21

That was. It was a great quarter for us. It was a very meaningful we we started initiated our first clinical trial for our nasal spray treatment for erectile dysfunction. So the product is called spontaneous and it's a world first product to treat erectile dysfunction.

0:37

Uh, so you're in a vital stage of the clinical trial journey. Tell us where you're at with that and what results you're seeing. Yeah. So we completed, uh, recruitment and dosing of all of our patients. And our study is quite, uh, uh, recruited very, very quickly. So that's a strong testament to the, the, the demand and interest for a new innovation in the erectile dysfunction, uh, sector. Um, so we're just in that data analysis phase. And in the upcoming quarter, we're going to be, uh, releasing those, uh, those final results, which is very exciting for us. This represents a world first, uh, clinical study. And there hasn't been really any new innovation in this erectile dysfunction space, uh, since Viagra came to marketplace. So, as you say, you recruited quickly for the study. So that kind of indicates some strong consumer demand. What exactly are you measuring in the trial? What are you hoping to see

1:30

now? The main issue with with tablets. So the pills on the marketplace, these are gold standard treatments, products like Viagra and Cialis is that they can take up to an hour to work. So they have to go through your digestive system. Uh, and so they don't work, uh, very, very fast. So men and their partners have to plan ahead and the same thing because they go through your digestive system. So your stomach and your liver, they're processed through those, those organs, uh, they make about 30% of men sick. So we bypass, uh, the digestive route and we go straight into the bloodstream, uh, through our through the nasal cavities, with our with our unique, uh, uh, first and kind nasal spray technology. So that bypasses those issues, overcomes those issues. And we're designed to work within 5 to 10 minutes. Uh, so really giving men and their partners the ability to live in the moment, uh, versus needing to plan ahead like they have to do now with gold standard products like Viagra. So as you say, you're going through the clinical trial, I assume after that it's towards manufacturing scale up and the like, talk us through the next stages of

2:30

the process. Yeah. So we have a very expedited path, uh, to marketplace. And we'll be working with our, our commercial manufacturing partners to scale up manufacturing, uh, post our clinical study here. Uh, and, uh, really looking to launch here in Australia in the second half of this calendar year through was called the special access and early access programs here that that give doctors the ability to prescribe new products that fill an unmet need. Uh, and there's, uh, such an unmet need in the erectile dysfunction space because, uh, men stop taking, uh, these, these, uh, these tablets in the first year because of those issues. Uh, uh, discussed. Are there any sort of negative implications you've been seeing in terms of, I guess, um, how healthy the accounts are from the trial so far?

3:17

Yeah. So we've, uh, uh, we our IPO, we just did a very successful IPO in December. Uh, those funds were geared to, uh, get us through our major milestones and through submissions to, uh, uh, the TGA here in Australia, but also, importantly, the US market and, and through the FDA process. Uh, so those funds were in a very strong and healthy position to meet those milestones and over the next 18 to 24 months. So what else is in the pipeline? Lee, given that you, as you say, your accounts balance looks quite healthy.

3:48

That we will be looking for early revenues, uh, uh, in the coming second half of this calendar year. Uh, with our product, uh, every doctor that I speak to, uh, is very interested in prescribing, uh, Spartan because they know that, uh, Viagra and some of those other tablets have issues in the marketplace, and men stop using it. And it's really a global issue with men and their partners. And it's being talked a lot about a lot more of this condition. And, uh, because it's such a, uh, it impacts people's lives and, and, uh, their mental health and their relationships. So, uh, we're really focused on getting spontaneity market and uh, first, uh, the first market, uh, being Australia with sales, uh, coming up in the second half of this calendar year. So we're really excited about that. What's your hope, Lee, in terms of the availability of this, uh, spray for the general public, is it going to be readily available? Is it going to be potentially on the PBS? Is it going to be cheap?

4:42

Yeah. So we'll definitely be targeting the PBS. But that's in about 12 to 18 months. Uh, uh, from from this time. In the meantime, we're going to be working with, uh, doctors and specialists in this sector in Australia to, uh, to allow them to prescribe, uh, to, uh, to their Ed patients, erectile dysfunction patients. Um, so that's right around the corner that, uh, it's very exciting for us, uh, as we launch, uh, and get ready to launch in the global markets in the coming year ahead.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy